Most cited papers in Chemotherapy-induced organ toxicity mitigation
What are the most cited papers in Chemotherapy-induced organ toxicity mitigation?
The most cited paper in Chemotherapy-induced organ toxicity mitigation is "Cisplatin in cancer therapy: Molecular mechanisms of action" (Shaloam R. Dasari, Paul Bernard Tchounwou, 2014), with 5,600 citations. Next come "Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma" (4,813) and "Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer" (2,878).
Showing 50 of 99 papers. Every paper with more than 462 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Cisplatin in cancer therapy: Molecular mechanisms of action Shaloam R. Dasari, Paul Bernard Tchounwou · European Journal of Pharmacology | 21 Jul 2014 | 5,600 |
| 2 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Bernard J. Escudier, Tim G Eisen, Walter Michael Stadler et al. · New England Journal of Medicine | 10 Jan 2007 | 4,813 |
| 3 | Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer William Patrick McGuire, William J. Hoskins, Mark F. Brady et al. · New England Journal of Medicine | 4 Jan 1996 | 2,878 |
| 4 | Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer Deborah Kay Armstrong, Brian N. Bundy, Lari B. Wenzel et al. · New England Journal of Medicine | 4 Jan 2006 | 2,644 |
| 5 | Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems Oktay Tacar, Pornsak Sriamornsak, Crispin R. Dass · Journal of Pharmacy and Pharmacology | 3 Aug 2012 | 2,482 |
| 6 | Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies Navjotsingh Pabla, Zheng Dong · Kidney International | 13 Feb 2008 | 1,925 |
| 7 | Carboplatin dosage: prospective evaluation of a simple formula based on renal function. A. Hilary Calvert, David R. Newell, Lindsey A. Gumbrell et al. · Journal of Clinical Oncology | Nov 1989 | 1,893 |
| 8 | Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects Ana-Maria Florea, Dietrich Büsselberg · Cancers | 15 Mar 2011 | 1,785 |
| 9 | Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy Daniela Maria Cardinale, Alessandro Colombo, Giulia Bacchiani et al. · Circulation | 6 May 2015 | 1,762 |
| 10 | The side effects of platinum-based chemotherapy drugs: a review for chemists Rabbab Oun, Yvonne E. Moussa, Nial Wheate · Dalton Transactions | 2018 | 1,735 |
| 11 | Mechanisms of Cisplatin Nephrotoxicity Ronald P. Miller, Raghu Kempegowda Tadagavadi, Ganesan Ramesh et al. · Toxins | 26 Oct 2010 | 1,631 |
| 12 | The status of platinum anticancer drugs in the clinic and in clinical trials Nial Wheate, Shonagh Walker, Gemma E. Craig et al. · Dalton Transactions | 2010 | 1,629 |
| 13 | Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study William C. W. Huang, Andrew S. Levey, Angel M. Serio et al. · The Lancet Oncology | 18 Aug 2006 | 1,618 |
| 14 | Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer Lawrence H. Einhorn, John Paul Donohue · Annals of Internal Medicine | Sep 1977 | 1,560 |
| 15 | Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients The RENAL Replacement Therapy Study Investigators · New England Journal of Medicine | 21 Oct 2009 | 1,481 |
| 16 | Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone Holcombe E. Grier, Mark Krailo, Nancy J. Tarbell et al. · New England Journal of Medicine | 19 Feb 2003 | 1,348 |
| 17 | Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer Caro Schaake-Koning, Walter Van den Bogaert, Otilia Dalesio et al. · New England Journal of Medicine | 20 Feb 1992 | 1,289 |
| 18 | Cisplatin Nephrotoxicity: A Review Xin Yao, Kessarin Panichpisal, Neil A. Kurtzman et al. · The American Journal of the Medical Sciences | Aug 2007 | 1,259 |
| 19 | Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer David Samuel Alberts, P. Y. Liu, Edward V. Hannigan et al. · New England Journal of Medicine | 26 Dec 1996 | 1,244 |
| 20 | Sunitinib in Patients With Metastatic Renal Cell Carcinoma Robert John Motzer, Brian I. Rini, Ronald M. Bukowski et al. · JAMA | 6 Jun 2006 | 1,230 |
| 21 | Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer Sandrine J. Faivre, Catherine Delbaldo, Karina Alejandra Osorio Vera et al. · Journal of Clinical Oncology | 29 Nov 2005 | 1,161 |
| 22 | Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Mark J. Ratain, Tim G Eisen, Walter Michael Stadler et al. · Journal of Clinical Oncology | 24 Apr 2006 | 1,036 |
| 23 | Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition Daniela Maria Cardinale, Alessandro Colombo, Maria Teresa Sandri et al. · Circulation | 14 Nov 2006 | 1,033 |
| 24 | Urothelial Carcinoma Associated with the Use of a Chinese Herb (Aristolochia fangchi) Joëlle Nortier, Marie-Carmen Muniz Martinez, Heinz H. Schmeiser et al. · New England Journal of Medicine | 8 Jun 2000 | 983 |
| 25 | Cisplatin Patrick J. Loehrer, LAWRENCE H. EINHORN · Annals of Internal Medicine | May 1984 | 951 |
| 26 | Preventing and Managing Toxicities of High-Dose Methotrexate Scott C. Howard, John N. McCormick, Ching‐Hon Pui et al. · The Oncologist | 5 Aug 2016 | 933 |
| 27 | Cisplatin nephrotoxicity István Arany, Robert L. Safirstein · Seminars in Nephrology | Sep 2003 | 907 |
| 28 | Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States Naga Chalasani, Robert J. Fontana, Herbert L. Bonkovsky et al. · Gastroenterology | 18 Sep 2008 | 906 |
| 29 | Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland Einar Stefan Bjornsson, Ottar Mar Bergmann, Helgi Kristinn Björnsson et al. · Gastroenterology | 16 Feb 2013 | 864 |
| 30 | Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Maurie M. Markman, Robert F. Rothman, Thomas B. Hakes et al. · Journal of Clinical Oncology | Mar 1991 | 860 |
| 31 | Characterization of a Novel, Water-Soluble Hydrogen Sulfide–Releasing Molecule (GYY4137) Ling Li, Matthew Whiteman, Yanyi Guan et al. · Circulation | 29 Apr 2008 | 842 |
| 32 | A Phase I and Pharmacological Study with Imidazolium- trans- DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent Jeany M. Rademaker-Lakhai, H.J.G.D. van den Bongard, Dick Pluim et al. · Clinical Cancer Research | Jun 2004 | 831 |
| 33 | Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer Steven E. Lipshultz, Stuart R. Lipsitz, Suzanne M. Mone et al. · New England Journal of Medicine | 29 Jun 1995 | 816 |
| 34 | Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions Rossella Marullo, Erica Werner, Natalya P. Degtyareva et al. · PLoS ONE | 19 Nov 2013 | 801 |
| 35 | Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986 Maria De Santis, Joaquim Bellmunt, Graham M. Mead et al. · Journal of Clinical Oncology | 13 Dec 2011 | 787 |
| 36 | Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron Tomáš Šimůnek, Martin Štěrba, Olga Popelová et al. · Pharmacological Reports | 2009 | 783 |
| 37 | The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group Paul Joseph Hesketh, Steven M. Grunberg, Richard J. Gralla et al. · Journal of Clinical Oncology | 20 Oct 2003 | 781 |
| 38 | Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. George D. Demetri, Mark G. Kris, James Lloyd Wade et al. · Journal of Clinical Oncology | Oct 1998 | 758 |
| 39 | TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity Ganesan Ramesh, William Brian Reeves · Journal of Clinical Investigation | 15 Sep 2002 | 754 |
| 40 | Cardiotoxicity of Chemotherapeutic Agents Vinita B. Pai, Milap C. Nahata · Drug Safety | 2000 | 736 |
| 41 | Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate Paul A. Meyers et al. · Journal of Clinical Oncology | 18 Mar 2005 | 724 |
| 42 | Pharmacokinetics and dosage adjustment in patients with renal dysfunction Roger Karel Verbeeck, Flora Tshinanu Musuamba · European Journal of Clinical Pharmacology | 19 Jun 2009 | 721 |
| 43 | Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting Richard J. Gralla, Loretta Marie Itri, Sharon E. Pisko et al. · New England Journal of Medicine | 15 Oct 1981 | 711 |
| 44 | Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy Matthew D. Galsky, Noah M. Hahn, Jonathan Rosenberg et al. · Journal of Clinical Oncology | 10 May 2011 | 710 |
| 45 | Pathophysiology of Cisplatin-Induced Acute Kidney Injury Abdullah Özkök, Charles L. Edelstein · BioMed Research International | 2014 | 707 |
| 46 | Drug-Induced Oxidative Stress and Toxicity Damian G. Deavall, Elizabeth Anne Martin, Judith Horner et al. · Journal of Toxicology | 2012 | 695 |
| 47 | Report of the United States Cooperative Study of Extracorporeal Shock Wave Lithotripsy George W. Drach, Study Coordinator, Stephen P. Dretler et al. · The Journal of Urology | Jun 1986 | 690 |
| 48 | Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury Takaharu Ichimura, Cheng Chieh Hung, Soon Ae Yang et al. · American Journal of Physiology-Renal Physiology | 3 Feb 2004 | 685 |
| 49 | Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro Ying Zhou, Huitao Xu, Wenrong Xu et al. · Stem Cell Research & Therapy | 25 Apr 2013 | 675 |
| 50 | Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury Vishal S. Vaidya, Victoria Ramírez, Takaharu Ichimura et al. · American Journal of Physiology-Renal Physiology | 20 Sep 2005 | 657 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.